Vascular Endothelial Growth Factor-Targeted Therapies in Advanced Renal Cell Carcinoma

被引:46
作者
Albiges, Laurence [1 ]
Salem, Mohamed [2 ]
Rini, Brian [2 ]
Escudier, Bernard [1 ]
机构
[1] Inst Gustave Roussy, Dept Med Oncol, F-94805 Villejuif, France
[2] Cleveland Clin Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44195 USA
关键词
Renal cell carcinoma; Clear cell carcinoma; Vascular endothelial growth factor; HIF; Bevacizumab; Sunitinib; Sorafenib; Pazopanib; VON-HIPPEL-LINDAU; TUMOR-SUPPRESSOR GENE; PHASE-I TRIAL; FACTOR RECEPTOR INHIBITOR; DAYS ON/7 DAYS; RAF KINASE; INTERFERON-ALPHA; SOLID TUMORS; BEVACIZUMAB; SAFETY;
D O I
10.1016/j.hoc.2011.04.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.
引用
收藏
页码:813 / +
页数:22
相关论文
共 61 条
[1]  
[Anonymous], PATIENT PREFERENCE S
[2]  
[Anonymous], PAZOPANIB VERSUS SUN
[3]  
[Anonymous], DAT FIL
[4]  
[Anonymous], AXITINIB AG 013736 D
[5]  
[Anonymous], Study to Compare Tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma
[6]  
[Anonymous], AXITINIB AG 013736 T
[7]   Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours [J].
Awada, A ;
Hendlisz, A ;
Gil, T ;
Bartholomeus, S ;
Mano, M ;
de Valeriola, D ;
Strumberg, D ;
Brendel, E ;
Haase, CG ;
Schwartz, B ;
Piccart, M .
BRITISH JOURNAL OF CANCER, 2005, 92 (10) :1855-1861
[8]  
Bhargava P, 2008, J CLIN ONCOL S1, V26
[9]  
Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154
[10]   VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10